Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, China.
Department of Pathology, YiYang Medical College, Yiyang, Hunan, China.
Sci Rep. 2018 Jan 24;8(1):1528. doi: 10.1038/s41598-018-19943-5.
RIZ1 has been studied as a tumor suppressor and may play a role in metabolic diseases related to the Western style diet, such as cancer and obesity. The Akt pathway is known to play a role in both cancer and obesity, and a link between Akt and RIZ1 has also been found. To better understand the role of RIZ1 in obesity and cancer, we investigated how RIZ1 regulates the expression of Akt3. We found that overexpression of RIZ1 in HEK293 cells reduced the expression of Akt3 protein. Luciferase reporter activity of Akt3 gene promoter was significantly reduced in cells co-transfected with RIZ1. Recombinant proteins of RIZ1 was able to bind the Akt3 promoter in vitro, and chromatin immunoprecipitation assay also demonstrated the ability of RIZ1 binding to the Akt3 promoter in vivo. Overexpression of RIZ1 increased H3K9 methylation on the Akt3 promoter. These results identify Akt3 as a target of RIZ1 regulation and expand our understanding of the Akt pathway in cancer and obesity.
RIZ1 被研究为一种肿瘤抑制因子,可能在与西方饮食相关的代谢性疾病中发挥作用,如癌症和肥胖症。Akt 通路已知在癌症和肥胖症中发挥作用,并且已经发现 Akt 和 RIZ1 之间存在联系。为了更好地理解 RIZ1 在肥胖症和癌症中的作用,我们研究了 RIZ1 如何调节 Akt3 的表达。我们发现,在 HEK293 细胞中过表达 RIZ1 会降低 Akt3 蛋白的表达。在共转染 RIZ1 的细胞中,Akt3 基因启动子的荧光素酶报告基因活性显著降低。重组 RIZ1 蛋白能够在体外结合 Akt3 启动子,染色质免疫沉淀分析也证明了 RIZ1 在体内结合 Akt3 启动子的能力。RIZ1 的过表达增加了 Akt3 启动子上的 H3K9 甲基化。这些结果确定了 Akt3 是 RIZ1 调节的靶标,并扩展了我们对癌症和肥胖症中 Akt 通路的理解。